Elicio Therapeutics, Inc (ELTX)

Over the past six months, Elicio Therapeutics' stock price has fluctuated, with a high of $14.93 on March 2, 2026, and a low of $4.61 on April 14, 2025. Key events include presentations at healthcare conferences, reports of inducement grants, and the release of full-year 2025 financial results. The company also reported antigen spreading in the Phase 2 AMPLIFY-7P trial and received a positive recommendation from the IDMC to continue the ELI-002 7P study. Additionally, the company secured $10 million in financing in Q2 2025, extending its cash runway, and reported 2024 financial results, including the completion of enrollment for the Phase 2 AMPLIFY-7P study.

As a clinical-stage biotechnology company, Elicio Therapeutics' products are still in development, so traditional demand seasonality does not apply. Demand is driven by clinical trial outcomes, regulatory approvals, and medical need rather than seasonal consumer trends.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, operating within the Healthcare sector, specifically in Biotechnology and Drug Discovery. The company uses its Amphiphile (AMP) platform to enhance the activation of cancer-specific T cells. Its lead product candidate is ELI-002, an AMP-modified mutant KRAS peptide antigen immunotherapy, with clinical trials including ELI-002 7P in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC).

Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts, and is incorporated in Delaware. The company's primary operations are based in the United States.

Elicio Therapeutics' brand reputation has been positively influenced by progress in clinical trials and presentations at healthcare conferences. ELI-002 7P achieved robust mKRAS-specific T cell responses in the Phase 2 AMPLIFY-7P trial, and positive interim data came from the Phase 1 study of ELI-002. The IDMC recommended continuing the ELI-002 7P study without modifications. Presentations at medical meetings like SITC and ESMO highlighted encouraging data.

Elicio Therapeutics has a diverse ownership structure, with 6.12% held by institutional investors, 31.17% by insiders, and 62.71% by retail investors. Retail investors hold the largest stake. Major institutional owners include Knoll Capital Management, LLC, and Vanguard Group Inc. Yekaterina Chudnovsky owns the most shares, holding 31% of shares outstanding.